Corticosteroid Pulse After Ablation (SAAB)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Radiofrequency ablation is an effective treatment for atrial fibrillation. However, about 20% of the time the atrial fibrillation recurs. Steroids given after the ablation may decrease inflammation caused by the ablation and thus improve healing and decrease the chance of recurrence of atrial fibrillation.
In this study patients will be randomized to receive intravenous steroids or not immediately following the ablation.
| Condition | Intervention | Phase |
|---|---|---|
|
Atrial Fibrillation |
Drug: Solumedrol Drug: Placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | SAAB: Randomized, Double Blind STudy of Corticosteroid Pulse After Ablation |
- Composite of severe symptomatic atrial arrythmias, clinically significant atrial arrhythmias lasting >24 hours requiring initiation or change in drug therapy, hospitalization for arrythmias or cardioversion during the initial 6 weeks post ablation [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
- Perception of cardiac pain assessed by a numerical pain scale [ Time Frame: one day and one week ] [ Designated as safety issue: No ]
- Occurrence of shortness of breath or edema requiring administration of a diuretic [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
- Need for repeat ablation [ Time Frame: 3 months ] [ Designated as safety issue: No ]
| Enrollment: | 120 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | December 2013 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Steroid |
Drug: Solumedrol
100mg, given once within 2 hours of the end of the ablation procedure
|
| Placebo Comparator: Placebo |
Drug: Placebo
Normal saline (1.6 cc)
|
Detailed Description:
Atrial fibrillation, a common arrhythmia, is the source of considerable morbidity. Prevalence of atrial fibrillation in adults is 0.5%, increasing to 10% in those patients over the age of seventy five. Numbers are expected to increase nearly 2.5 fold over the next 50 years. Radiofrequency (RF) ablation to cure atrial fibrillation has become an established and effective therapy in the many atrial fibrillation patients. However, approximately 20% return with recurrent atrial fibrillation after ablation.
RF ablation directly targets the substrate for atrial fibrillation, cauterizing cardiac tissue through the application of radiofrequency energy , causing a myocardial lesion which effectively blocks the errant pathway. This process of RF ablation induces an inflammatory effect. As the lesion heals it often enlarges. This may contribute to recurrence of atrial fibrillation after ablation, as well as increased pain. There is some early evidence that a single dose of corticosteroids after ablation may improve the healing process, thus decreasing pain and incidence of recurrent atrial fibrillation.
The aim of the study is to determine the usefulness of a one time dose of solumedrol following radiofrequency ablation for atrial fibrillation..
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18
- Drug refractory, symptomatic paroxysmal atrial fibrillation
Exclusion Criteria:
- Contraindication to solumedrol
- Persistent or permanent Atrial Fibrillation
- Previous history of radiofrequency ablation for atrial fibrillation
Contacts and Locations| United States, Minnesota | |
| Abbott Northwestern Hospital | |
| Minneapolis, Minnesota, United States, 55407 | |
| Principal Investigator: | Daniel P Melby, MD | Minneapolis Heart Institute |
More Information
Publications:
| Responsible Party: | Minneapolis Heart Institute Foundation |
| ClinicalTrials.gov Identifier: | NCT00807586 History of Changes |
| Other Study ID Numbers: | ep002 |
| Study First Received: | December 10, 2008 |
| Last Updated: | April 23, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Minneapolis Heart Institute Foundation:
|
Atrial Fibrillation Corticosteroid Radiofrequency catheter ablation for atrial fibrillation |
Additional relevant MeSH terms:
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Methylprednisolone acetate Prednisolone acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone Prednisolone hemisuccinate Prednisolone phosphate Anti-Inflammatory Agents Therapeutic Uses |
Pharmacologic Actions Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents |
ClinicalTrials.gov processed this record on May 22, 2013